17:35 , Nov 29, 2017 |  BioCentury  |  Emerging Company Profile

Gluten-free gut

PvP Biologics Inc. is developing an oral enzyme therapy for celiac disease to break down gluten in the stomach with more specificity than a competing enzyme cocktail. The company’s KumaMax, a synthetic peptidase, should prevent...
20:41 , Jun 27, 2017 |  BC Extra  |  Financial News

Provention raises $28.4M in series A

Autoimmune and inflammatory disease prevention and interception play Provention Bio Inc. (Lebanon, N.J.) said it raised $28.4 million in a series A round from the Johnson & Johnson Innovation-JJDC Inc. arm of Johnson & Johnson...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

Amgen, Celimmune deal

Amgen granted Celimmune exclusive, ex-Japan rights to develop and commercialize AMG 714 . Celimmune is planning Phase II trials of the human mAb against IL-15 to treat diet non-responsive celiac disease and refractory celiac disease,...
01:42 , Mar 3, 2015 |  BC Extra  |  Company News

Celimmune licenses Amgen's celiac candidate

Amgen Inc. (NASDAQ:AMGN) granted Celimmune LLC (Bethesda, Md.) exclusive, worldwide rights outside of Japan to develop and commercialize AMG 714, a human mAb against IL-15. Amgen has an exclusive option to reacquire AMG 714 after...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Company News

Celimmune autoimmune, cancer news

Newco Celimmune launched to acquire, develop and commercialize therapeutics to treat and prevent immune disorders. The company will initially focus on diet non-responsive celiac disease and refractory celiac disease, which is a T cell lymphoma...